An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation

Abstract

Ovarian cancer is characterized by the establishment of tolerance, the recurrence of disease, as well as a poor prognosis. Gene signatures in ovarian cancer cells enable cancer medicine research, therapy, prevention, & management problematic. Notwithstanding advances in tumor puncture surgery, novel combinations regimens, and abdominal radiation, which can provide outstanding reaction times, the bulk of gynecological tumor patients suffer from side effects & relapse. As a consequence, more therapy alternatives for individuals with ovarian cancer must always be studied to minimize side effects and improve progression-free and total response rates. The development of cancer medications is presently undergoing a renaissance in the quest for descriptive and prognostic ovarian cancer biomarkers. Nevertheless, abnormalities in the BRCA2 or BRCA1 genes, a variety of hereditary predispositions, unexplained onset and progression, molecular tumor diversity, and illness staging can all compromise the responsiveness and accuracy of such indicators. As a result, current ovarian cancer treatments must be supplemented with broad-spectrum & customized targeted therapeutic approaches. The objective of this review is to highlight recent contributions to the knowledge of the interrelations between selected ovarian tumor markers, various perception signs, and biochemical and molecular signaling processes, as well as one’s interpretation of much more targeted and effective treatment interventions.

FBXL18 is required for ovarian cancer cell proliferation and migration through activating AKT signaling

“…Because of its highly lethal characteristics and lack of suitable biomarkers for diagnosis and treatment, OC has become a major malignancy that threatens women's health and quality of life [14]. FBXL18 has been identified as an E3 ubiquitin ligase and is widely involved in the tumorigenesis of many tumors, such as hepatocellular carcinoma (HCC) [15], glioma [13], and bladder cancer [8].…”